Search

Your search keyword '"UTERINE SEROUS CARCINOMA"' showing total 681 results

Search Constraints

Start Over You searched for: Descriptor "UTERINE SEROUS CARCINOMA" Remove constraint Descriptor: "UTERINE SEROUS CARCINOMA"
681 results on '"UTERINE SEROUS CARCINOMA"'

Search Results

1. Concordance of HER2 Expression in Paired Primary and Metastatic Sites of Endometrial Serous Carcinoma and the Effect of Intratumoral Heterogeneity

2. Concordance of HER2 Expression in Paired Primary and Metastatic Sites of Endometrial Serous Carcinoma and the Effect of Intratumoral Heterogeneity.

3. Expression of netrin‐1 in uterine serous carcinoma and its association with prognosis.

4. Sulindac exhibits anti-proliferative and anti-invasive effects in uterine serous carcinoma cells.

5. Germline genetic testing reveals pathogenic variants in uterine serous carcinoma patients

6. High-dose ascorbate exerts anti-tumor activities and improves inhibitory effect of carboplatin through the pro-oxidant function pathway in uterine serous carcinoma cell lines.

7. The comparison of pure uterine serous carcinoma and mixed tumor with serous component: a single-institution review of 91 cases

9. Mapping three-dimensional intratumor proteomic heterogeneity in uterine serous carcinoma by multiregion microsampling

11. Assessment of the differences in oncologic outcomes between patients with high‐grade serous ovarian carcinoma and uterine serous carcinoma.

12. Ipatasertib, an oral AKT inhibitor, in combination with carboplatin exhibits anti-proliferative effects in uterine serous carcinoma

13. Neoadjuvant chemotherapy in patients with stage IVB uterine serous carcinoma: a Turkish multicentric study.

14. Ipatasertib, an oral AKT inhibitor, in combination with carboplatin exhibits anti-proliferative effects in uterine serous carcinoma.

15. Ultrasonographic evaluation of endometrial stripe thickness is insufficient to rule out uterine serous carcinoma.

16. Construction and validation of nomograms for predicting the prognosis of elderly patients with uterine serous carcinoma: a SEER-based study.

17. HER2 in uterine serous carcinoma: Current state and clinical perspectives.

18. Neoadjuvant chemotherapy in patients with stage IVB uterine serous carcinoma: a Turkish multicentric study

19. HER2 Oncogene as Molecular Target in Uterine Serous Carcinoma and Uterine Carcinosarcoma.

20. Laparoscopy with or without robotic assistance does not negatively impact long-term oncologic outcomes in patients with uterine serous carcinoma.

21. Effect of the combination of trastuzumab, paclitaxel and carboplatin in the treatment of uterine serous carcinoma: A systematic review and meta-analysis.

22. Oxidative stress‐induced FAK activation contributes to uterine serous carcinoma aggressiveness

23. 子宫浆液性癌20例分子学特征及临床分析.

24. Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers.

25. Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy

26. Prognostic Value of Peritoneal Cytology in Stage I Serous and Clear Cell Carcinoma of the Endometrium.

27. Oxidative stress‐induced FAK activation contributes to uterine serous carcinoma aggressiveness.

28. Breast Cancer Patients Are at Increased Risk of Developing Uterine Serous Cancer: Implications for Counseling – A SEER Analysis.

29. Adjuvant therapy in women with early stage uterine serous carcinoma: A multi-institutional study.

30. Targeted Therapies in the Treatment of Uterine Serous Carcinoma.

31. Prevalence and Prognostic Relevance of Homologous Recombination Repair Gene Mutations in Uterine Serous Carcinoma.

32. HER2 in Uterine Serous Carcinoma: Testing platforms and implications for targeted therapy.

33. Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu.

34. Conditional estimates for uterine serous cancer: Tools for survivorship counseling and planning.

35. Oncologic safety of laparoscopic surgery for women with apparent early-stage uterine serous carcinoma: A multi-institutional retrospective cohort study.

36. Oncological Safety of Diagnostic Hysteroscopy for Apparent Early-Stage Type II Endometrial Cancer: A Multicenter Retrospective Cohort Study.

37. A 4-gene signature predicts prognosis of uterine serous carcinoma

38. Oncological Safety of Diagnostic Hysteroscopy for Apparent Early-Stage Type II Endometrial Cancer: A Multicenter Retrospective Cohort Study

39. A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma

40. Real-world outcomes in patients with advanced endometrial cancer: A retrospective cohort study of US electronic health records.

41. Uterine serous carcinoma: role of surgery, risk factors and oncologic outcomes. Experience of a tertiary center.

42. Utility of a custom designed next generation DNA sequencing gene panel to molecularly classify endometrial cancers according to The Cancer Genome Atlas subgroups

43. Evaluation of the incidence and clinical significance of WT-1 expression in uterine serous carcinoma

44. Optimal cytoreduction followed by chemoradiation in stage IVB uterine serous carcinoma

45. Germline genetic testing reveals pathogenic variants in uterine serous carcinoma patients.

46. DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo.

47. A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline Mutation.

48. Metastatic serous endometrial carcinoma to the ureter

49. Concomitant diagnosis of endometrial and breast cancer - does the sequence matters?

50. Efficacy of hyperthermic intraperitoneal chemotherapy and interval debulking surgery in women with advanced uterine serous carcinoma

Catalog

Books, media, physical & digital resources